Open Orphan, the Dublin-listed pharmaceutical services company run by Cathal Friel, has announced that its hVIVO subsidiary has signed a £5 million contract with a European biotechnology company.
Under the terms of the contract, the European biotech company will test its intravenous antiviral candidate using the Hvivo human challenge study model for respiratory syncytial virus , an illness which affects the respiratory tract of children and at-risk adults. In severe cases it can...
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: businessposthq - 🏆 8. / 71 Read more »
Source: businessposthq - 🏆 8. / 71 Read more »